Seer Inc

Innovative Eyewear shares surged 63% after the company reported preliminary second-quarter net sales of approximately $0.99 million, a 71% year-over-year increase, and announced new retail partnerships in Canada and the United States. The company received an initial purchase order from a Canadian optical retail group with 345 locations and was awarded a 50-store test with a major U.S. retailer, both expected to begin in the third quarter of 2026. Separately, Seer jumped 35% after its Chair and CEO proposed to acquire all outstanding Class A shares for $2.45 per share in cash plus two contingent value rights, with the board forming a special committee to evaluate the offer. Orthofix and Enovis rallied over 15% each after CMS withdrew reimbursement changes for non-invasive bone growth stimulators, restoring Medicare rates to pre-May 2026 levels. Other notable movers included YD Bio, up 23% on no specific news, and Adlai Nortye, which gained 15% amid progress updates on its cancer therapy pipeline.

Seer shares jumped 26% premarket on Monday after the life science firm said it received an unsolicited, non-binding proposal from its CEO Omid Farokhzad to acquire all outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights. Seer’s board of directors will establish a special committee consisting solely of independent directors to review the proposal.

Seer, Inc. announced receipt of an unsolicited, non-binding acquisition proposal from its CEO and Chair Omid Farokhzad. Farokhzad offered to purchase all outstanding Class A shares at $2.45 per share in cash, plus two separate contingent value rights. The company intends to assemble a Special Committee of independent directors to evaluate the offer. SEER closed Thursday at $1.62, down 0.61%, but rose 41.98% to $2.30 in afterhours trading.

Seer announced that the European Patent Office will maintain its European Patent No. EP4056263 covering particle-based enrichment for proteomics, and the U.S. International Trade Commission has instituted an investigation into Nanomics Biotechnology's importation of products Seer alleges infringe five of its U.S. patents. The EPO decision followed an opposition seeking revocation of the patent, which is owned by The Brigham and Women's Hospital and exclusively licensed to Seer. The ITC investigation, stemming from a complaint filed in May 2026, concerns Nanomics' Proteonano kits and workstations, with Seer seeking a limited exclusion order to bar their importation and sale in the United States. These developments add to a growing record of validation for Seer's patent estate, which includes more than 250 patent applications and issued patents worldwide.